Sweden
· Delayed Price · Currency is SEK Xbrane Biopharma AB Company Description
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars.
The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial spondylitis.
It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis.
The company was incorporated in 2008 and is headquartered in Solna, Sweden.
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Martin Amark |
Contact Details
Address: Scheeles väg 5 Solna, 171 65 Sweden | |
| Phone | 46 8 55 90 56 00 |
| Website | xbrane.com |
Stock Details
| Ticker Symbol | XBRANE |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007789409 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Siavash Bashiri | Chief Operating Officer, Head of Biosimilars and Deputy Chief Executive Officer |
| Martin Amark | Chief Executive Officer |
| Associate Prof. Jan-Willem De Gier | Co-Founder |
| Dr. Samuel Wagner Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Jane Benyamin | Interim Chief Financial Officer and Head of IR |
| Dr. David Vikstrom | Chief Technology Officer |
| Dina Jurman | Head of Clinical Affairs |
| Anders Wallstrom | Head of Manufacturing and Supply Chain |
| Håkan Yildirim | Head of Intellectual Property |